Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (Nasdaq:BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 29,809,471 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase in our authorized shares of common stock at an exercise price of $0.66 per share of common stock and will expire on the fifth anniversary of such initial exercise date.
Related news for (BNTC)
- Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
- Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
- Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
- Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
- Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update